-
Mashup Score: 0Relationship Between BCL-2 Expression and Venetoclax Concentration Among Patients With AML - 9 hour(s) ago
Higher levels of BCL-2 expression at time of diagnosis may be associated with worse outcomes while higher blood concentrations of venetoclax may have an impact on timing of adverse reactions among patients with AML, according to a recent study.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
According to results from a phase 2 trial, following the amendment of chemotherapy regimen to FLOT, the addition of trastuzumab with or without pertuzumab did not improve progression-free survival or overall survival for patients with HER2-positive gastric cancers.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Oncologists1Tweet-
According to results from the EORTC-1203 GITC “INNOVATION” trial, the addition of #trastuzumab, with or without #pertuzumab, to #FLOT chemotherapy did not improve PFS or OS in comparison to FLOT. Learn more: https://t.co/eRkNHftUgm #ASCOGI25 #medtwitter #onctwitter https://t.co/4eOad4oxmg
-
-
Mashup Score: 0Pevonedistat and Belinostat Therapy Demonstrates Safety, Modest Activity for Patients With R/R Acute Myeloid Leukemia or High-Risk MDS - 1 day(s) ago
According to results from a dose escalation phase 1 study, combination belinostat and pevonedistat therapy for relapsed/refractory acute myeloid leukemia or high-risk MDS demonstrated some activity and limited toxicity.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Oncologists1Tweet-
Combination #belinostat and #pevonedistat therapy for R/R #AML or high-risk #MDS demonstrated some activity and limited toxicity. Learn more: https://t.co/rq8tjR4vXm #MedTwitter https://t.co/HSWBS1AucE
-
-
Mashup Score: 0
According to an exploratory analysis of the NAPOLI 3 trial, dose reductions of liposomal irinotecan or oxaliplatin did not negatively impact the overall survival among patients with metastatic pancreatic ductal adenocarcinoma.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Oncologists1Tweet-
A post hoc analysis of the phase 3 #NAPOLI trial found that dose reductions of liposomal irinotecan or oxaliplatin didn't affect OS in patients with metastatic pancreatic ductal adenocarcinoma treated with #NALIRIFOX. Learn more: https://t.co/CaUrgmve8C #medtwitter #onctwitter https://t.co/qS4eWiCogo
-
-
Mashup Score: 0FDA Approves Trastuzumab Deruxtecan for HR-Positive, HER2-Low/-Ultralow Breast Cancer - 2 day(s) ago
Based on results from the phase 3 DESTINY-Breast 06 trial, the FDA has approved trastuzumab deruxtecan for patients with HR-positive, HER2-low or HER2-ultralow unresectable or metastatic breast cancer who experienced disease progression on or after 1 or more prior lines of endocrine therapy in the metastatic setting.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Oncologists1Tweet-
The @US_FDA has approved trastuzumab deruxtecan for patients with HR-positive, HER2-low/-ultralow breast cancer. Learn more: https://t.co/lgl1WRi0OS #medtwitter #onctwitter #FDAapproval https://t.co/Qzb6r9XAYT
-
-
Mashup Score: 0Olutasidenib and Azacitidine Show Efficacy and Durability for Treatment of R/R mIDH1 Acute Myeloid Leukemia - 2 day(s) ago
Olutasidenib and azacitidine combination therapy for relapsed/refractory acute myeloid leukemia demonstrated durable patient responses and safety.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Oncologists1Tweet-
#Olutasidenib and #azacitidine combination therapy for relapsed/refractory #AML demonstrated durable patient responses and safety. Learn more: https://t.co/N63Qdco2el #MedTwitter https://t.co/UEHUcLrA8H
-
-
Mashup Score: 0Promising Efficacy With Bevacizumab Plus Pembrolizumab for Platinum-Resistant Nasopharyngeal Carcinoma - 2 day(s) ago
Results from a phase 2 study found that the addition of bevacizumab to pembrolizumab had superior efficacy to pembrolizumab alone among patients with platinum-resistant recurrent or metastatic nasopharyngeal carcinoma.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Oncologists1Tweet-
Phase 2 study results demonstrated that #bevacizumab plus #pembrolizumab is superior to #pembrolizumab alone among patients with platinum-resistant recurrent or metastatic nasopharyngeal carcinoma. Learn more: https://t.co/M8XMDroisz #medtwitter #onctwitter https://t.co/nQeYBbxASE
-
-
Mashup Score: 0Second-Line Fedratinib Shows Promise for Patients With Myelofibrosis With Low Baseline Platelet Counts - 5 day(s) ago
According to the phase 3 randomized FREEDOM2 Trial, fedratinib demonstrated spleen volume reduction and symptom reduction versus best available therapy among patients with myelofibrosis previously treated with ruxolitinib.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Oncologists1Tweet-
#Fedratinib demonstrated spleen volume reduction and symptom reduction versus best available therapy among patients with #myelofibrosis previously treated with #ruxolitinib. Learn more: https://t.co/fXMFT5W0u1 https://t.co/RSEb5OkUhH
-
-
Mashup Score: 1
Anne Marijn Kramer, MD, PhD, discusses follow-up data from a phase 1 trial showing that CD22-directed CAR-T therapy provides durable remissions and long-term survival after 3 years for patients with large B-cell lymphomas progressing after CD19-directed CAR-T therapy.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Oncologists1Tweet-
Anne Marijn Kramer, MD, PhD, discusses showing CD22-directed CAR-T therapy provides durable remissions and long-term survival after 3 years for patients with LBCL progressing after CD19-directed CAR-T therapy. Learn more: https://t.co/vGmGLUqlLa #ASH2024 https://t.co/EMG1TNEhF6
-
-
Mashup Score: 4
Jean-Nicolas Champagne, MD, discusses results from a retrospective study that showed retreatment with R-CHOP-like therapy was a reasonable option for late-relapse DLBCL and resulted in durable remission in a high proportion of patients.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Oncologists1Tweet-
Jean-Nicolas Champagne, MD, discusses retreatment with R-CHOP-like therapy for late-relapse #DLBCL at the 66th ASH Annual Meeting in San Diego, California. Learn more: https://t.co/uwDShOumd5 #ASH2024 https://t.co/YTw9RMcGvO
-
Higher levels of BCL-2 expression at time of diagnosis may be associated with worse outcomes while higher blood concentrations of #venetoclax may have an impact on timing of adverse reactions among patients with #AML. Learn more: https://t.co/gAHg0yzsjQ https://t.co/ELD3hSdTl3